A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs PMZ 1620 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 20 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 16 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Jul 2015, as reported by ClinicalTrials.gov.